News

Validating its shock reduction research and technology, Medtronic Inc. announced the results of three clinical trials, Shock-Less, PainFree SST and ADVANCE III, which successfully employed...

A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The implantable cardioverter-defibrillator (ICD) prevents...

The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at...

New data from 100,438 patients with Boston Scientific implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds...

St. Jude Medical Inc. has received CE Mark approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy...

Wearable cardioverter defibrillators (WCD) can be an effective therapy option for patients with a transient or undefined arrhythmic risk, according to the WEARIT-II Registry, the largest...

Biotronik announced the U.S. Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D...

The Population Health Research Institute (PHRI) has conducted a further independent analysis of data received from ongoing prospective registries that monitor the performance of the St. Jude...

Tyrx Inc. has received a license from Health Canada to market its new AigisRx R Fully Resorbable Antibacterial Envelope technology with implantable electronic devices (IEDs). The AigisRx R...

Biotronik Iforia ICD/CRT-D CE-Approval

Biotronik received CE mark for its most advanced ICD/CRT-D (implantable cardioverter defibrillator/cardiac resynchronization therapy device) series. Iforia is the world’s first DF4 ICD/CRT-D...

ACC HRS Appropriate Use Criteria ICDs CRTs

The American College of Cardiology (ACC) and Heart Rhythm Society (HRS), along with key specialty societies, released appropriate use criteria for implantable cardioverter-defibrillators (ICDs)...

Weight Loss American College of Cardiology ICD Implants Risk

Even minor weight loss is associated with worse health outcomes among patients implanted with a certain type of defibrillator known as cardiac resynchronization therapy with defibrillator (CRT-D...

Zoll wearable defibrillator

Oklahoma Heart Hospital (OHH), Oklahoma’s first dedicated heart hospital, has excelled at creating quality outcomes through an integrated approach to patient care. To maintain this culture of...

Heart Failure Treatments EP Lab ICDs JAMA Internal Medicine St. Louis University

New research at Saint Louis University shows physicians do not talk to patients about the psychosocial impact and long-term risks of implanting cardioverter defibrillators (ICDs) to treat...

Lumax 740 DX system, ICD

The U.S. Food and Drug Administration (FDA) granted final approval for the Biotronik Lumax 740 DX system. The device is a first-in-class implantable cardiac defibrillator (ICD...

In response to the astounding percentage of inappropriate and non-compliant ICD, CRT-P and CRT-D device implantations each year, Think Tank Medical has developed and released its CMS ICD...

My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013...

The U.S. Food and Drug Administration (FDA) has cleared St. Jude Medical’s new version of its Merlin.net Patient Care Network (PCN). The secure, Internet-based remote care system is for...

August 20, 2012 — Zoll Medical Corp., a manufacturer of medical devices and related software solutions, announced that physicians at all of the 17 “Honor Roll” hospitals and all of the 50 “Best...

Biotronik Home Monitoring ECOST Clinical Trial ICDs

Biotronik announced that the European Heart Journal has published the clinical results of the ECOST trial (...